Perceptions in physicians and pharmacists are a common impediment to the utilization of generic medicines in clinical practice. As a multinational initiative to accelerate access to high-quality generic medicines, Dr Reddy’s Laboratories Ltd has developed the Generic dRug Adoption Framework. Currently available in four languages (English, Portuguese, Spanish, and Russian) and four (Malaysia, Brazil, Colombia, and Ukraine) countries, the framework will enable physicians and pharmacists to identify high-quality generics and help towards switching from originator to generic medicines. This can help to increase the adoption and access for generic medicines. The platform is not intended to guide treatment decisions but can help healthcare providers to differentiate a high-quality generic medicine based on parameters of effectiveness, safety, quality, and costs.
ToverudELHartmannKHåkonsenH.A systematic review of physicians' and pharmacists' perspectives on generic drug use: what are the global challenges?Appl Health Econ Health Policy2015;
13(Suppl 1): S35–S45.
3.
ColganSFaasseKMartinLRet al.
Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review.BMJ Open2015;
5:e008915.
4.
YangYTNagaiSChenBKet al.
Generic oncology drugs: are they all safe?Lancet Oncol2016;
17: e493–501.
5.
BocklischFBocklischSFKremsJF.Sometimes, often, and always: exploring the vague meanings of frequency expressions.Behav Res Methods2012;
44: 144–157.
6.
KesselheimASMisonoASLeeJLet al.
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.JAMA2008;
300: 2514–2526.
7.
ChowS-CLiuJP.Design and analysis of bioavailability and bioequivalence studies. 3rd ed.
Boca Raton:
CRC Press, 2009.
8.
AboudalleIKantarjianHMBurgerJAet al.
Efficacy and safety of generic imatinib after switching from innovator imatinib in patients treated for chronic myeloid leukemia. Blood2017;
130: 2906.
9.
ShrankWHCoxERFischerMAet al.
Patients’ perceptions of generic medications: although most Americans appreciate the cost-saving value of generics, few are eager to use generics themselves.Health Affairs2009;
28: 546–556.
10.
SteinJDShekhawatNTalwarNet al.
Impact of the introduction of generic latanoprost on glaucoma medication adherence.Ophthalmology2015;
122940: 738–747.
11.
BettoMFaresJSalibaNet alEfficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients.Ann Saudi Med2017;
37: 366–374.
12.
SachaTGóra-TyborJSzarejkoMet al.
A multicenter prospective study on efficacy and safety of imatinib generics: a report from Polish Adult Leukemia Group imatinib generics registry.Am J Hematol2017;
92: E125–E128.
13.
HowlandRH.Are generic medications safe and effective?J Psychosoc Nurs Ment Health Serv2010;
48: 13–16.
14.
DasMChoudhurySMaitySet al.
Generic versus branded medicines: an observational study among patients with chronic diseases attending a public hospital outpatient department.J Nat Sci Biol Med2017;
8: 26–31.
15.
IyerGMarimuthuSPSegalJBet al.
An algorithm to identify generic drugs in the fda adverse event reporting system.Drug Saf2017;
40: 799–808.
16.
PramodKTahirMACharooNAet al.
Pharmaceutical product development: a quality by design approach.Int J Pharm Invest2016;
6: 129–138.
17.
Al AmeriMNNayuniNAnil KumarKGet al.
The differences between the branded and generic medicines using solid dosage forms: in-vitro dissolution testing.Results Pharm Sci2011;
2: 1–8.
Alfonso-CristanchoRAndiaTet al.
Definition and classification of generic drugs across the world.Appl Health Econ Health Policy2015;
13(Suppl 1): S5–11.
25.
DunneSSShannonBCullenWet al.
Beliefs, perceptions and behaviours of GPs towards generic medicines.Fam Pract2014;
31: 467–474.
26.
HassaliMAKongDCMStewartK.Generic medicines: perceptions of general practitioners in Melbourne, Australia.J Generic Med2006;
3: 214–225.
27.
ČatićTAvdagićLMartinovićI.Knowledge and attitudes of physicians and pharmacists towards the use of generic medicines in Bosnia and Herzegovina.Med Glas2017;
14: 25–32.
28.
HassaliMAAlrasheedyAAMcLachlanAet al.
The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharm J2014;
22: 491–503.
GargAAkkuSKhandarkarS.Cost-minimization analysis of generic equivalents (bortezomib, decitabine and capecitabine) in comparison to the originator brand medicines in Colombia.Generics Biosimilars Initiat J2016;
5: 164–167.
AllanGMLexchinJWiebeN.Physician awareness of drug cost: a systematic review.PLoS Med2007;
4: e283.
33.
SchutteTTichelaarJNanayakkaraPet al.
Students and doctors are unaware of the cost of drugs they frequently prescribe.Basic Clin Pharmacol Toxicol2017;
120: 278–283.
34.
MishukAUQianJHowardJNet al.
The association between patient sociodemographic characteristics and generic drug use: a systematic review and meta-analysis.J Manag Care Spec Pharm2018;
24: 252–264.
35.
SchafheutleEIHassellKNoycePRet al.
Access to medicines: cost as an influence on the views and behaviour of patients.Health Soc Care Commun2002;
10: 187–195.
36.
ChuCLalLSFelderTMet al.
Evaluation of patient assistance program eligibility and availability for top 200 brand name and generic drugs in the United States. Innov Pharm2012;
3: 1–9.
37.
ColemanCIReddyPQuerciaRAet al.
Cost benefit analysis of a pharmacy-managed medication assistance program for hospitalized indigent patients.Am J Health Syst Pharm2003;
60: 378–382.
38.
GillespieELPatelAAHenyanNNet al.
Economic analysis of a medication assistance program for ambulatory care patients at an urban teaching clinic. Formulary2006;
41: 31–34.
